Research and Markets: iPS Cell Generation Patent Landscape – 2013/03

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/pwn4hc/ips_cell) has announced the addition of the "iPS cell Generation patent landscape - 2013/03" report to their offering.

Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged tissues using differentiated cells out of stem cells. However, ethical and scientific issues are related to the use of embryonic stem cells. In this context, induced pluripotent stem cells (iPS) appear as a promising approach. The patient's somatic cells are first dedifferentiated into iPS cells and then redifferentiated into the cell of interest.

This revolutionary technology represents major scientific, societal and economic challenges and was recently rewarded by a Nobel Prize in Physiology and Medicine to Prof. Shinya Yamanaka and Prof. John Gurdon.

With over 1000 patent families qualified and analyzed out of a pool of 3000 patent families, we have analysed:

- The iPS cells generation patent landscape

- The iPS cells differentiation patent landscape

- The iPS cells database

Reasons To Buy

- Identify key inventors and players involved in the generation and differentiation of iPS cells

More here:
Research and Markets: iPS Cell Generation Patent Landscape - 2013/03